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Abstract
Cancer is one of the leading causes of death in Malta. Palliative care is a 
mainstay in the care of such patients. Commonly encountered symptoms 
include pain, nausea and vomiting, constipation and oropharyngeal 
complications. All of these bear an impact on the quality of life of the 
patient and also of the carers. Drug treatment is an integral part of the 
management of these symptoms. Patients and their carers may have 
concerns regarding their medication. The community pharmacist is well 
positioned and competent to support the needs of these patients as part 
of their holistic care.
Introduction
Palliative care involves the care of patients 
with advanced terminal disease, taking a 
holistic approach to dealing with issues that 
patients and their relatives encounter in their 
day-to-day activities. 
This paper specifically focuses on palliative 
care for cancer patients. During 2014, 932 
(or 28.5%) of the total number of deaths 
registered in Malta were due to cancer, with 
people over the age of 65 years accounting 
for almost 75% of cancer deaths. Over 80% 
of these deaths occurred in hospital, just 
under 10% at their residence and another 6% 
in care homes.1 This paper will focus on the 
control of common symptoms - pain, nausea 
and vomiting, constipation and oropharyngeal 
complications. The general principles of such 
management can be applied to other advanced 
non-malignant conditions with terminal 
outcomes, such as neurological disorders. 
However cancer patients remain the main 
beneficiaries of such care offered both in 
hospital as well as the community.
Hospice for terminally ill patients has 
been established for over 150 years, with 
the first hospice founded in France back in 
1842.  During the past 50 years the concept of 
hospice has developed rapidly to also include 
care outside the hospital environment.2
This article does not focus on the 
“terminal phase”, last few days or hours 
of life, where an increased level of care is 
required. During this phase, symptoms such 
as pain, nausea and constipation change 
little in prevalence but additional symptoms 
such as asthenia, dry mouth, confusion and 
breathlessness may take priority. During this 
phase the need for drug treatment including 
the routes by which drugs are administered 
requires careful evaluation. In such a setting 
clinical pharmacists’ intervention in medicines 
management goes beyond drug reviews and 
will require particular expertise with regards 
to mixing of parenteral medicines and their 
subsequent stability.
Panel 1: WHO definition of palliative care
“The active total care of patients 
whose disease is not responsive to 
curative treatment. Control of pain, of 
other symptoms, and of psychological, 
social and spiritual problems is 
paramount. The goal of palliative care 
is achievement of the best quality of 
life for patients and their families.”
Medicines management in 
the palliative care 
of cancer patients
Educational aims
•	 To provide information on the conventional and off licence use of medicines 
•	 To provide the rationale behind choices of drug treatment of common symptoms 
•	 To update on the precautions to be taken with respect to different medicines and 
highlight recent drug safety issues
•	 To empower pharmacists to be more active in the education and support of palliative 
care patients and their carers
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Management of cancer pain
Pain is a frequent symptom in patients with 
cancer, with substantial impact on their 
quality of life. Despite the availability of 
opioid analgesics and updated guidelines, 
under treatment is still frequently 
encountered.3 Careful assessment of the 
patient, including factors that aggravate 
or relieve the pain, is essential if adequate 
analgesia is to be achieved. Patients also 
have concerns with regards to side-effects 
including dependence and addiction. Such 
misconceptions can lead to refusal of pain 
relief and a reduction in patients’ quality of 
life. Palliative patients should have adequate 
pain relief medication and fear of addiction 
should not restrict adequate pain relief 
treatment. Counselling is thus an important 
component in ensuring effective pain 
management. 
Principles of treatment of cancer pain
The World Health Organization (WHO) pain 
ladder, originally devised for the treatment of 
cancer pain, is a well established guideline 
for the management of patients with chronic 
pain. The analgesic treatment should start 
with drugs indicated by the WHO analgesic 
ladder appropriate for the severity of pain. 
This guideline recommends the use of 
conventional analgesics including non-
steroidal anti-inflammatory drugs (NSAID’s), 
paracetamol and opioids. Opioids are 
classified into two categories according to 
their efficacy (strong and weak opioids). 
Adjuvant analgesics can be used at any step 
if indicated (Refer to Figure 1).4
Step 1: Mild pain - Non-opioid 
analgesics such as paracetamol or non-
steroidal anti-inflammatory drugs are 
indicated. To improve outcomes, patients 
should be advised to take their pain relief 
medication at regular intervals rather than 
on an “as required” basis.4,5,6
Step 2: Mild to moderate pain - A weak 
opioid (codeine, tramadol), should be used 
in combination with a non-opioid analgesic. 
The prescribing of combinations of weak 
opioids is not recommended. If a patient is 
not responding to maximum doses of a weak 
opioid/ non-opioid combination then it is 
appropriate to move up to step 3.4,5,6
Step 3: Moderate to severe pain - 
Strong opioid analgesics are required. 
Once a patient is stabilised on a dose of 
immediate-release opioid, he/she should 
be switched to the equivalent dose of a 
modified-release preparation if possible. An 
immediate-release formulation should also 
be prescribed on an “as-required” basis for 
breakthrough pain episodes. The equivalent 
dose should be approximately 1/6th of the 
daily dose.4,5,6 
Measurement of cancer pain
A number of validated pain assessment scales 
have been developed to enable the making 
of consistent, repeated assessments. Complex 
tools such as the McGill pain questionnaire 
are generally too time-consuming for 
daily use and simpler scales such as visual 
analogue scales (VAS), verbal rating scales 
(VRS) or numerical rating scales (NRS) are 
routinely used. 
The equivalence of each category in 
the WHO classification of pain intensity on 
the numerical rating scale and the relevant 
pharmacological management is shown in 
Table 1.5,6 
Drugs used for analgesia
Non-opioids
Paracetamol remains the main non-opioid 
used for the treatment of cancer pain. Non-
steroidal anti-inflammatory drugs (NSAIDs) 
may also be prescribed. There is no evidence 
to support the preference of one NSAID 
over another. Prescribing of NSAIDs should 
be based on knowledge of the side-effect 
profile and previous response to individual 
drugs. NSAIDs should be used with caution 
in patients with cardiovascular disease. In 
the presence of gastro-intestinal (GI) risk 
factors a proton pump inhibitor should be 
co-prescribed with all NSAIDs including COX-
2 inhibitors. The long-term use of NSAIDs 
Figure 1: WHO Pain Relief Ladder4
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The range of strong opioids available to 
prescribers locally is limited, with morphine 
being the most frequent prescribed opioid 
for the relief of severe pain. At the initiation 
of treatment or when changing treatment 
the patient’s dose should be titrated until 
an adequate maintenance dose is reached. 
Patients should be prescribed maintenance 
treatment on a regular basis at the appropriate 
dose which relieves pain throughout the dosing 
including COX-2 inhibitors has to be carefully 
monitored and reassessed periodically 
because they can provoke severe toxicity 
such as GI bleeding, platelet dysfunction and 
renal failure. COX-2 selective inhibitors may 
increase the risk of thrombotic cardiovascular 
adverse reactions and do not protect against 
renal failure.5,6,7
Opioids
The opioids are classified as the weak opioids 
(e.g. codeine, tramadol) and the strong 
opioids (e.g. morphine, fentanyl). 
Prescribing a high dose of a weak opioid 
can result in an opioid load comparable to a 
low dose of a strong opioid (i.e., 100mg of 
codeine is roughly equivalent to 10mg of oral 
morphine). Weak opioids can have the same 
adverse effects as strong opioids, so patient 
counselling should be the same. 
A ceiling analgesic effect is observed 
with weak opioids. Increasing the dose of a 
weak opioid beyond the maximum licensed 
dose will not improve analgesia but expose 
the patient to more pronounced adverse 
effects. A maximal ceiling analgesic effect is 
not observed with strong opioids.5,6,7
Panel 2: Codeine, dihydrocodeine  
and tramadol
Codeine is a pro-drug and has to be 
metabolised to morphine mainly via 
CYP2D6 liver enzyme in order to have 
an analgesic effect.8,9 Up to 7% of 
Caucasian populations may have a 
deficiency in CYP2D6 resulting in an 
inadequate analgesic effect.9
Dihydrocodeine is an active 
substance. It is also a substrate for 
CYP2D6, however there is no evidence 
that inhibition of this enzyme reduces 
analgesic effect.8
Tramadol has clinically relevant 
serotonergic activity. It should be 
avoided in patients taking TCA and SSRIs 
due to the risk of serotonin toxicity. It 
also lowers seizure threshold.8
interval without causing unmanageable adverse 
effects.
The dose should be titrated with caution in 
patients with risk factors: impaired renal function, 
impaired hepatic function, chronic respiratory 
disease, compromised upper airway, sleep apnoea. 
Dose increments should be based upon total 
opioid dose taken in the previous 24 hours. The 
rapidity of the dose escalation should be related 
to the severity of the symptoms. Opioid switching 
can also improve response by at least 50 per cent.
The appropriate formulation should be used 
for maintenance dose. When tolerated, morphine 
via the oral route of administration should be 
advocated as first choice, unless the patient is 
nil by mouth. Transdermal fentanyl patches are 
a useful option in patients unable to swallow. 
Patches are also useful in patients with worsening 
renal function, intolerable side-effects (e.g. 
intractable constipation) and patients with poor 
concordance.
Management of breakthrough pain
Breakthrough pain should be managed using short 
acting medication (refer to Table 2). Typically 
“as required” doses are calculated as one sixth 
of the 24 hour oral regular dose given every 4 
hours as needed. Whereas this approach is useful 
for titration of the background opioid dose it 
may not be appropriate for breakthrough pain 
characterised by quick onset and short duration.10
Table 1: Pharmacological management of cancer pain
Pharmacological management
Mild Mild to moderate Moderate to severe
  
Numerical rating scale 1-3 Numerical rating scale 4-6 Numerical rating scale 7-10
Non-opioids Titration of weak opioid  Strong opioids
Paracetamol Codeine Morphine
   
NSAID’s Tramadol Fentanyl
Non-selective NSAIDs
COX-2 selective inhibitors +/- NSAIDs/paracetamol
+/- adjuvant analgesic
Causes of breakthrough pain Management
Incidental to specific activities (e.g. dressing change, physiotherapy) Potentially managed with short-acting opioids given in 
 anticipation of these events
End of dose failure pain Potentially managed by increasing the dose of regularly 
 scheduled opioid
Uncontrolled persistent pain Potentially managed by increasing the dose of regularly  
 scheduled opioid
Table 2: Causes of breakthrough pain and their management
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Management of opioid adverse effects
Opioids have a number of adverse effects. 
The management of these side-effects is 
an integral part of palliative care (refer to 
Table 3). Constipation and nausea are the 
two most commonly encountered side-
effects of opioids. The management of such 
adverse effect involves the prophylactic use 
of stimulant laxatives and faecal softeners for 
the duration of opioid treatment plus possibly 
anti-emetics for the first few days of opioid 
treatment.8, 11
Adverse effect Management
Constipation Stimulant laxative + stool softener (titrate stool softener/     
 laxative as needed to get bowel movement every one to      
Very common  two days) If impacted consider phosphate enema 
(≥ 1/10)  
 Laxatives only treat constipation and can exacerbate  other symptoms of  
 opioid-induced bowel dysfunction; they do not address the 
 cause of the problem.  
 For intractable chronic constipation, consider an alternative opioid e.g.  
 switch to fentanyl 
 Ensure adequate hydration
Nausea Prochlorperazine 10mg qds PRN PO
Very common Metoclopramide 10mg-15mg qds PRN PO
(≥ 1/10)
 Haloperidol 0.5mg-1.0mg tds or qds PRN PO
 Domperidone 10mg tds PO
 Change PRN to regular if nausea persists
Pruritus Antihistamines e.g. promethazine 10mg-20mg bd to tds PO;  
 Hydroxizine 25mg up to qds PO
Common  Consider changing to another opioid
(>1%)
Respiratory depression and sedation  Naloxone can be used in case of respiratory depression. Administer by iv 
 injection, 0.4 -2.0mg, if no response to be repeated at intervals of 2 to 3minutes  
Uncommon to a maximum of 10mg. Further doses may be necessary if respiratory function 
(<1%) deteriorates.
  Consider dose reduction of opioid
Table 3: Adverse effects of opioids and their management
Adjuvant analgesia
The choice of a category of drugs, or a 
specific drug for adjuvant analgesia depends 
on a number of factors including type of pain 
(i.e. nociceptive or neuropathic), source of 
pain, co-morbidities and current medication 
(refer to Table 4). It is quite common to 
use low starting doses of adjuvants for 
neuropathic pain. Adjuvants can have opioid-
sparing effects and the dose of the opioid 
should be carefully reviewed as the adjuvant 
is titrated.5,11
Panel 3: Bisphosphonates
About 50% of patients benefit, typically 
in one to two weeks, and this may 
last for 2 to 3 months. In those who 
respond, continue to treat PRN for as 
long as there is benefit. 
Benefits are seen mainly with 
intravenous bisphosphonates. 
Bisphosphonates are poorly absorbed 
when given orally, and this is reduced 
further by food. Oral bisphosphonates 
are contra-indicated in patients with 
oesophageal abnormalities, strictures 
and achalasia and inability to stay 
upright for 60 minutes.11
Panel 4: Systemic corticosteroids
Systemic corticosteroids are used off-label 
for pain relief for pain caused by a tumour 
in a confined organ or body cavity, for 
example raised intracranial pressure and 
bone pain. Dexamethasone is the most 
frequently used corticosteroid for disease 
suppression. 
Cautions with corticosteroids: Diabetes 
mellitus, psychotic illness. Although there 
is only a small increase in risk of peptic 
ulceration with corticosteroids alone, 
when given concurrently with NSAIDs the 
risk increases up to 15 times. Prolonged 
courses of corticosteroids increase 
susceptibility to infections and their 
severity.11
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Management of nausea and vomiting
Nausea and vomiting are common symptoms 
experienced by patients who are receiving 
palliative care. The prevalence of such 
symptoms tends to increase as disease 
progresses and is estimated to be up to 70% 
in patients with advanced cancer.12
Pharmacological management is the 
mainstay in treatment of these symptoms; 
however good health care strategies such as 
maintenance of oral hygiene and regularising 
bowel habit should be ensured.  Such 
measures may also help postpone the need 
for anti-emetics. Where appropriate any 
reversible causes of nausea and vomiting 
should be treated.13
Optimal emetic control in the acute 
phase is essential to prevent nausea and 
vomiting in the delayed phase. Treatment 
of nausea and vomiting in palliative care 
cancer patients depends on the cause of the 
symptoms and patient’s preference.
Principles of antiemetic treatment
Antiemetics are to be selected according to 
the likely cause of emesis. A combination 
of two or more antiemetics is needed in 
over 25% of cases of chronic nausea.14 
Drug combinations may be used as long as 
the drugs chosen do not act on the same 
receptor. Drug combinations having the 
same mode of action increase the risk of 
side-effects without additional clinical 
benefit.11,15
The emetic risk with intravenous 
chemotherapy is divided into four categories 
(high, moderate, low and minimal) based 
on the Grunberg classification. Antiemetics 
are commenced before chemotherapy, if 
indicated. Oral doses are to be administered 
at least 30 minutes before chemotherapy 
is initiated. Domperidone is usually started 
on the evening of chemotherapy. Patients 
who receive highly emetogenic agents 
receive ondansetron or Aprepitant and 
dexamethasone as their pre- and post- 
chemotherapy schedule. For patients who 
receive chemotherapy with a moderate 
risk of causing nausea and vomiting the 
two-drug combination of a 5HT3 antagonist 
(ondansetron) and dexamethasone is 
recommended. For chemotherapy that carries 
a low risk of producing nausea, a single dose 
of dexamethasone is recommended prior 
to chemotherapy. No antiemetic agent is 
routinely recommended before or after low 
risk chemotherapy to prevent nausea and/
or vomiting.
For patients who receive high risk radiation 
therapy a 5 HT3 antagonist before each 
radiation fraction, and at least 24 hours after 
completing radiation therapy is recommended. 
Patients should also be given a 5 day course 
of dexamethasone during fractions 1 to 5 of 
radiation.
Dexamethasone should be prescribed 
prophylactically when indicated and not as a 
treatment for emesis. The risk and benefits of 
the use of steroids in diabetic patients and 
in patients who are immunosuppressed are 
to be carefully considered before prescribing. 
Dexamethasone should be given no later 
than 2.00pm to minimise wakefulness in the 
night.16,17,18
Drugs used for the treatment of nausea and 
vomiting
Various classes of drugs are used to control 
symptoms of nausea and vomiting (Refer to Table 
5). The most commonly used drugs are prokinetic 
agents (e.g. metoclopramide and domperidone) 
as well as agents acting principally on the 
chemoreceptor trigger zone (e.g. haloperidol 
and domperidone). Drugs with prokinetic action 
are blocked by anticholinergic drugs (example 
amitriptyline, hyoscine and ondansetron) and 
thus such combinations are not recommended.11,15
Table 4: Indications for adjuvant analgesics 
Indication  Treatment
Inflammation  Trial of NSAIDs or corticosteroids
Bone  NSAIDs and titrate analgesic to effect 
 Consider trial of bone-modifying agents (bisphosphonates) 
 For diffuse bone pain consider hormonal therapy or chemotherapy, corticosteroids  
 (and/or systemic administration of radioisotopes) 
 For local bone pain consider non-pharmacological interventions such as  
 radiotherapy and nerve block
Neuropathic pain  Tricyclic antidepressants (Amitriptyline and nortriptyline) 
 Anti-convulsants (carbamazepine, gabapentine, pregabaline) 
 Corticosteroids
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Class Examples Indications
Dopamine antagonists Haloperidol Mainly used for drug-induced nausea and vomiting
Histamine/ anticholinergic antagonists Cyclizine Mainly used when there is raised intracranial  
  pressure, motion sickness or mechanical bowel  
  obstruction.
Serotonin antagonists Ondansetron Prevention and treatment of nausea and vomiting  
  induced by cytotoxic chemotherapy and  
  radiotherapy.
Prokinetics Metoclopramide Radiotherapy-induced nausea and vomiting as well  
 Domperidone as for delayed (but not acute) chemotherapy-  
  induced nausea and vomiting.
NK-1 receptor antagonists Aprepitant Chemotherapy induced nausea and vomiting and  
  inhibits both the acute and delayed phases of  
  cisplatin-induced emesis. Augments anti-emetic  
  activity of 5HT3 receptor antagonists and 
  Dexamethasone
Corticosteroids Dexamethasone Adjuvant in the prevention of nausea and vomiting 
(adjuvant use)  (off-label use)
Antipsychotics * Levomepromazine Levomepromazine by injection can be used in  
 (off-label use)  terminally ill patients requiring an anti-emetic and  
  a sedative
*Benzodiazepines may be used in the management of nausea and vomiting due to their anxiolytic action.
 Table 5. Medicines used as antiemetics: indications, side-effects and contra-indications
Panel 5 Antiemetics: drug safety updates
Domperidone 19 There is a small increased risk of serious cardiac side effects particularly in the  
 elderly, patients on total daily doses of more than 30 mg, or taking QT-prolonging  
 medicines or potent CYP3A4 inhibitors. The cardiac risk profile of domperidone  
 should be taken into account if there is a clinical need to use this drug.
Metoclopramide 20,21 A recent EU review has confirmed the well known risks of neurological effects such  
 as short-term extrapyramidal disorders and tardive dyskinesia. The review   
 concluded that these risks outweigh the benefits in long-term or high-dose and  
 recommended changes that include a restriction to the dose and duration of use to 
 help minimise the risk of potentially serious neurological adverse effects. 
Ondansetron 22,23,24 Dose- dependent prolongation of QTc interval and cardiac arrhythmia, including  
 Torsade de Pointes, are known risks with ondansetron. Thus caution must be used  
 if administering ondansetron to patients with such risk factors.
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Management of constipation in cancer care
Constipation in advanced cancer is generally a 
multi-factorial issue. It can be affected by the 
nutritional status of the patient, weakness, the 
underlying disease and drugs.
Principles of treatment
The aim of drug management is to restore the 
amount of water in the faeces and improve 
rectal evacuation.
Traditionally a combination of a bowel 
stimulant with a faecal softener is used. The 
concurrent use of several different laxatives 
is not recommended. Laxative doses should 
be titrated every couple of days according to 
response. If the maximum recommended or 
tolerated dose is not effective, an alternative 
preparation is to be used.25
Rectal products (suppositories or 
enemas) are sometimes indicated when oral 
treatment has failed or in patients with 
specific conditions such as paralysis, frailty 
or immobility. Rectal products should be 
avoided in patients who are neutropenic 
or thrombocytopenic because of the risk of 
infection or bleeding.11
Drugs used for the constipation
Commonly prescribed laxatives include osmotic 
laxatives (e.g. lactulose syrup and macrogols) 
and stimulant laxatives (e.g. senna and 
bisacodyl). Osmotic laxatives retain water 
in the gut with a subsequent increase in 
faecal volume. Stimulant laxatives improve 
intestinal motility by a direct contact with 
the submucosal and myenteric plexus causing 
muscle contraction. They also increase water 
secretion into the bowel lumen.
Management of oropharyngeal complications 
Palliative patients, particularly those receiving 
chemotherapy and/or head and neck radiation 
may have various oral complications. 
Such complications can occur as a direct 
result of malignancies or as a result of the 
treatment that the patient might have had.  
Complications include: mucositis, xerostomia 
(dry mouth), gum disease and tooth decay.26
Elimination of oral disease and 
implementation of oral care protocols designed 
to maintain maximum oral health must be 
components of care before, during and after 
chemotherapy and radiation therapy. Regular, 
systematic oral care hygiene, including a 
combination of tooth brushing using a soft-
toothbrush, flossing and one or more bland 
non-medicated oral rinses and moisturisers 
are to be used to maintain oral hygiene for all 
cancer treatment modalities. 
Ongoing oral assessment and treatment 
of complications are essential. Nutritional 
issues as well as drug administration 
should also be considered. The alterations 
of formulations of oral medication (tablet 
crushing, capsule opening) to assist patients 
with swallowing difficulties are in most cases 
unlicensed. 
Treatment of oropharyngeal complications 
Oral ulceration (mucositis)
Simple mouthwashes e.g. 0.9% saline can 
be soothing, help maintain oral hygiene 
and prevent secondary infection. Advising 
to use at a tepid temperature may be more 
soothing. Alcohol-based mouth rinses should 
be avoided.
Protecting the ulcerated area by coating 
agents are of limited value because they can 
be difficult to apply and they do not relieve 
persistent inflammatory pain.
As mucositis severity increases and 
topical pain management strategies become 
less effective, it becomes increasingly 
necessary to depend on systemic analgesics 
to manage oral radiation mucositis pain. 
Pain relief in the form of topical analgesics 
is available in various formulations 
including gels, sprays and oral rinses. These 
formulations include anaesthetics and 
NSAIDs. Benzydamine mouthwash (an NSAID) 
can be used to prevent oral mucositis in 
patients with head and neck cancer receiving 
moderate dose radiation therapy (up to 50 
Gy) without concomitant chemotherapy. 
Topical anaesthetics or other agents should 
be considered to promote oral comfort and 
provide short-term pain relief. 
Antimicrobial lozenges should not be 
used to prevent oral mucositis in patients 
receiving radiation therapy for head and neck 
cancer. 27,28
Xerostomia (dry mouth)
Saliva helps maintain a healthy balance 
of bacteria in the mouth. Without saliva 
pathogenic organisms can colonise the 
mouth. This can cause sores and mouth 
infection, including thrush that is caused by 
an overgrowth of yeast. Saliva also washes 
away acids and food particles left in the 
mouth after eating, which means that a lack 
of saliva can cause gum disease and cavities. 
Dry mouth may make it difficult to wear 
dentures. 
Chemotherapy and radiation treatments 
cause dry mouth by damaging the salivary 
glands. Chemotherapy causes dry mouth by 
making saliva thicker, which is usually a 
temporary symptom that clears up about 2 to 
8 weeks after treatment ends. 
Dry mouth can also be a side-effect of 
treatment with certain medicines including 
antidepressants, diuretics and some analgesics. 
Other causes of dry mouth include mouth 
infections such as thrush and dehydration.29
The underlying cause should be treated, 
where possible. Unless a main salivary duct 
is blocked, a saliva stimulant is preferable. 
Chewing gum is useful. When advising on 
chewing gum a sugar free brand should be 
recommended. In addition a low tec brand is 
more suitable in patients with dentures.
Artificial saliva is a poor substitute for 
natural saliva. Artificial saliva with a neutral 
pH is an option for patients who cannot 
tolerate saliva stimulants.   Pilocarpine (a 
muscarinic agent) is indicated for xerostomia 
after radiotherapy for head and neck cancer. 
After radiotherapy, up to 3 drops of 4% eye 
drops tds (equivalent to 6mg tds) can be 
administered. This is off-label use of the eye 
drops, pilocarpine tablets are not available 
locally.11
Oral candidiasis
Oropharyngeal candidiasis is a common 
oropharyngeal complication in palliative 
care patients, ranging from 13 to 30%. 
This may increase during head and neck 
radiation therapy and in patients who receive 
concurrent chemotherapy.30
Treatment of candidiasis
Topical antifungal agents such as nystatin 
or clotrimazole can be effective. These can 
be presented as gels or drops. In order to 
increase the contact time of the drug with the 
mucosa, food should not be taken immediately 
after drugs have been administered. 
Patients using dentures should remove 
the denture before using a topical antifungal 
agent and should also treat the dentures to 
avoid repeat colonisation.11
For moderate to severe infections and 
persistent lesions, systemic agents such as 
fluconazole are preferred. Patients who receive 
oral antifungals should be asked to avoid 
eating, drinking or rinsing for at least 30 
minutes after use.11
Preparations for the topical treatment of 
oral complications
There are various preparations for the topical 
treatment of oropharyngeal complications, 
including the use of off-label and 
extemporaneously prepared medicines (Table 
6).31
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Administration of medication to patients 
with swallowing difficulties
Patients or their carers may attempt to 
modify the medication without seeking 
advice from a health care professional. 
Pharmacists are competent to advise and 
optimise treatment in such situations.  
Although, in many cases, the modification 
of drugs (crushing of tablets, opening of 
capsules) is unlikely to cause harm to the 
patient evidence supporting this practice 
is currently limited. Certain medication 
such as modified release tablets, enteric 
coated tablets, hormonal and cytotoxic 
preparations should never be crushed 
or opened. The tampering with such 
medication may compromise the safety 
of the patient or the carer. Formulation 
tampering is in most cases unlicensed by 
the manufacturer. 
Liquid formulations still remain the first 
choice alternative for solid dosage forms 
in patients who retain some ability to 
swallow. Alternative formulations that 
avoid the need of swallowing e.g. patches 
and oro-dispersable formulations are 
increasingly being made available. 
Panel 6: Cytotoxic tablets - do not crush
All health care workers should avoid 
contact with cytotoxic drugs and hormones 
(e.g. methotrexate and tamoxifen). 
There is a risk of cytotoxic powder being 
aerosolized if cytotoxic tablets are crushed, 
exposing care workers to hazardous 
materials.
Conclusion
The pharmacist is in a strategic position 
to provide holistic care for palliative care 
patients and their carers. When dispensing 
and counselling about medicines pharmacists 
should consider the rationale behind choices 
of drug treatment. Aspects of patient 
behaviour which affect concordance should be 
given appropriate consideration. Pharmacists 
can support seamless care by improving access 
to medication, carrying out medication reviews 
and bridging communication between different 
health care professionals, patients and their 
carers. 
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Preparation Therapy Recommended dose Precautions
Saline mouthwash Oral hygiene Frequent intervals Made up with warm water
Chlorhexidine 0.2% 
mouthwash (with alcohol)
Topical antiseptic
10ml rinsed in mouth for one 
minute twice a day
Alcohol-based mouth 
rinses should be avoided in 
mucositis and dry mouth
Chlorhexidine 0.2% alcohol 
free mouthwash
Topical antiseptic
10ml rinsed in mouth for one 
minute twice a day
Alcohol free preparation is to 
be used where there is oral 
ulceration
Benzydamine 0.15% 
mouthwash Topical anti-inflammatory 
NSAID. 
Used for the relief of post-
radiation mucositis
10-15ml rinsed in mouth 
every 1.5-3 hours when 
required. Not usually longer 
than seven days duration
Only used in patients aged 13 
years and older
Benzydamine 0.15% oro-
mucosal spray
Four to eight sprays applied 
to affected area every 1.5-3 
hours
None relevant
Orabase Mucoadhesive Used as required None relevant
Hydrocortisone mucoadhesive 
buccal tablets
Topical corticosteroid
2.5mg tablet dissolved slowly 
in the mouth four times a day
Increased risk of candidiasis
Beclometasone 50mcg inhaler 
(unlicensed indication)
Topical corticosteroid
50 – 100mcg twice daily on 
the oral mucosa
Increased risk of candidiasis
Lidocaine 5% ointment Local anaesthetic
Rub sparingly and gently on 
affected area
Avoid prolonged use. Avoid 
anaesthesia of the pharynx 
before meals due to risk of 
choking
Choline salicylate dental gel
Analgesic for mild oral and 
perioral lesions
Apply gel with gentle 
massage. Not more often that 
every 3 hours
Contra-indicated in children 
under 16 years of age
Artificial saliva
Spray
Gel
Treatment of dry mouth To be applied as required
 Table 6: Topical therapies used for oral conditions
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Key points
•	 Patients should be treated adequately for pain relief. Chronic pain should be treated 
with analgesics given at regular intervals and ‘as required’ medication for break 
through pain. 
•	 Use of opioids should not be restricted due to fear of addiction to opioids. 
•	 In additional to conventional analgesics, adjuvant medication is sometimes 
indicated in order to improve pain control. Such medication can have opioid-
sparing effects.
•	 Opioids reduce bowel tone and contractility, predisposing patients to constipation. 
A combination of a faecal softener plus a stimulant laxative should be prescribed 
prophylactically on starting treatment with opioids.
•	 There are various causes of nausea and vomiting in palliative cancer patients 
and treatment of these symptoms will depend on their cause and the patient’s 
preference.
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